mRNA vaccines to prevent malaria infection and stop mosquito transmission
mRNA-LNP vaccines targeting multiple stages and multiple species of human malaria parasite
This project is developing mRNA vaccines designed to both prevent malaria infection and block mosquitoes from spreading P. falciparum and P. vivax among people at risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | George Washington University NIH-funded |
| Lab location | 1 site (Washington, United States) |
| Project ID | NIH-11251774 on NIH RePORTER |
What this research studies
From your point of view, researchers are using mRNA packaged in lipid nanoparticles to teach the immune system to recognize key malaria proteins from both the form that infects people and the form passed to mosquitoes. They plan to combine targets from early liver-stage parasites (like the circumsporozoite protein) and sexual-stage gametocyte proteins (like Pfs25 and Pfs230) so a single vaccine could both reduce illness and cut transmission. The work will start with laboratory and preclinical testing to find the best antigen combinations and formulations. If those steps succeed, the most promising candidates would be advanced toward human vaccine trials in people living in malaria-affected regions.
Who could benefit from this research
Good fit: Ideal candidates would include people living in or traveling to regions where P. falciparum and P. vivax are common and healthy volunteers who qualify for future vaccine studies.
Not a fit: People with severe immune suppression, those with known allergies to vaccine components, or individuals not exposed to malaria are unlikely to receive direct benefit from this early-stage research.
Why it matters
Potential benefit: If successful, this approach could produce stronger, longer-lasting vaccines that both protect individuals from malaria and reduce spread in communities.
How similar studies have performed: Approved vaccines like RTS,S and R21 have given partial, short-lived protection, and while mRNA vaccines proved highly effective for COVID-19, mRNA malaria vaccines are a newer approach that has limited human testing so far.
Where this research is happening
Washington, United States
- George Washington University — Washington, United States (Active)
Researchers
- Principal investigator: Kumar, Nirbhay — George Washington University
- Study coordinator: Kumar, Nirbhay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.